LOCALLY ADVANCED BREAST CANCER (LABC)
Clinical trials for LOCALLY ADVANCED BREAST CANCER (LABC) explained in plain language.
Never miss a new study
Get alerted when new LOCALLY ADVANCED BREAST CANCER (LABC) trials appear
Sign up with your email to follow new studies for LOCALLY ADVANCED BREAST CANCER (LABC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Engineered immune cells take on Hard-to-Treat breast cancer
Disease control OngoingThis early-stage study tests a new two-part treatment for people with advanced breast cancer that has stopped responding to standard therapies. Participants receive a single infusion of their own engineered immune cells (CLBR001) followed by cycles of an antibody drug (ABBV-461).…
Matched conditions: LOCALLY ADVANCED BREAST CANCER (LABC)
Phase: PHASE1 • Sponsor: Calibr, a division of Scripps Research • Aim: Disease control
Last updated May 20, 2026 11:53 UTC
-
Virus therapy trial for breast cancer pulled before starting
Disease control TerminatedThis study was designed to test the safety and effectiveness of a new virus-based treatment (BioTTT001) combined with standard pre-surgery therapy for women with locally advanced breast cancer. The trial was withdrawn before enrolling any participants, so no results are available…
Matched conditions: LOCALLY ADVANCED BREAST CANCER (LABC)
Phase: PHASE1 • Sponsor: Beijing Bio-Targeting Therapeutics Technology Co., Ltd • Aim: Disease control
Last updated May 18, 2026 12:01 UTC